4-FLUORO-2-(TRIFLUOROMETHYL)BENZOIC ACID

We are 4-FLUORO-2-(TRIFLUOROMETHYL)BENZOIC ACID CAS:141179-72-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-FLUORO-2-(TRIFLUOROMETHYL)BENZOIC ACID
CAS.NO:141179-72-8
Synonyms:4-FLUORO-2-(TRIFLUOROMETHYL)BENZOIC ACID
4-fluoro-2-trifluoromethylbenzoic acid
2-trifluoromethyl-4-fluorobenzoic acid
Molecular Formula:C8H4F4O2
Molecular Weight:208.11000
 
Physical and Chemical Properties:
Density:1.489
Melting point:121-124ºC
Boiling point:239ºC
Flash point:98.3ºC
 
Specification:
Appearance:White crystalline powder
Assay:≥99.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

4-FLUORO-2-(TRIFLUOROMETHYL)BENZOIC ACID


Related News: “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business.(S)-2-(1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).2-Chloro-3-picoline CAS:18368-76-8 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”

Related Products
Product Name
4-Fluoro-2-methoxyaniline View Details
ethyl (1S,3aR,6aS)-octahydrocyclopenta[c]pyrrole-1-carboxylate hydrochloride View Details
3,3-diphenylpropanenitrile View Details
1-Fluoro-3,5-bis(trifluoromethyl)benzene manufacturer (4R,6R)-tert-Butyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate manufacturer 3-trimethoxysilylpropyl acetate manufacturer L-Histidine Monohydrochloride Monohydrate manufacturer 4-(4-Pyridyl)-1-butanol manufacturer